Sanofi-kymab-deal: Sanofi’s acquisition of a clinical-stage biopharmaceutical company Kymab
Global pharmaceutical company, Sanofi will acquire a clinical-stage biopahrmaceutical company Kymab. Sanofi will acquire Kymab for an upfront payment of approximately $1.1... Read More
Chugai received MHLW, Japan marketing authorization for humanized anti-PD-L1 monoclonal antibody, Tecentriq to treat unresectable advanced/recurrent NSCLC
Posted on29 Dec 2020
Comments0
Chugai Pharmaceutical announced that it has obtained regulatory approval for its humanized anti-PD-L1 monoclonal antibody, Tecentriq Intravenous Infusion 1200 mg [generic name:... Read More
AstraZeneca – Alexion $39 billion deal
Posted on15 Dec 2020
Tagsacquisition in pharma, global pharma deals, largest ever pharma deal, monoclonal antibody, pharma deal, ravulizumab, Soliris, Ultomiris
Comments0
AstraZeneca has agreed to buy US drugmaker Alexion Pharmaceuticals for $39 billion to bolster its positions in immunology and rare diseases. Alexion... Read More
AbbVie, Eisai received new indication approval for Humira to treat pyoderma gangrenosum
AbbVie GK and Eisai Co, Ltd announced an approval of additional indication of Humira, a fully human anti-TNFa monoclonal antibody, for the... Read More
Case Study – Inmazeb: USFDA Approval of first ebola medicine
U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a combination of three monoclonal antibodies, as the first FDA-approved treatment... Read More